CD4 and neoplasm: Approximately 10% of patients with GC receiving PD-1 blockade progress rapidly (45), to hyper-progressive disease, which is related to Treg cell proliferation in tumor tissue (46), an increase in immunosuppressive CD4+ T cell subset that hinders effective anti-tumor immunity (47–52).